Hims & Hers Health (NYSE:HIMS) Given New $23.00 Price Target at Jefferies Financial Group

Hims & Hers Health (NYSE:HIMS) had its target price raised by Jefferies Financial Group from $14.00 to $23.00 in a research report released on Thursday morning, Benzinga reports. The firm currently has a hold rating on the stock.

A number of other research firms have also issued reports on HIMS. TheStreet upgraded shares of Hims & Hers Health from a d rating to a c rating in a report on Monday, March 4th. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $14.00 to $16.00 and gave the company a hold rating in a report on Tuesday, May 7th. Citigroup lowered Hims & Hers Health from a buy rating to a neutral rating and increased their price target for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Canaccord Genuity Group started coverage on Hims & Hers Health in a research report on Wednesday, April 10th. They set a buy rating and a $20.00 price objective for the company. Finally, Seaport Res Ptn reaffirmed a buy rating on shares of Hims & Hers Health in a report on Friday, April 26th. Seven analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of Moderate Buy and a consensus price target of $17.00.

Hims & Hers Health Stock Down 7.2 %

Shares of NYSE HIMS opened at $20.01 on Thursday. The business’s 50 day moving average is $17.42 and its two-hundred day moving average is $13.41. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $25.74. The firm has a market cap of $4.30 billion, a price-to-earnings ratio of -2,001.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. The firm had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.05) EPS. Analysts anticipate that Hims & Hers Health will post 0.19 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,546 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $22.21, for a total value of $256,436.66. Following the completion of the sale, the chief financial officer now directly owns 177,449 shares of the company’s stock, valued at approximately $3,941,142.29. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Hims & Hers Health news, insider Michael Chi sold 17,303 shares of Hims & Hers Health stock in a transaction on Monday, June 24th. The shares were sold at an average price of $22.07, for a total value of $381,877.21. Following the transaction, the insider now directly owns 185,326 shares in the company, valued at $4,090,144.82. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,546 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $22.21, for a total transaction of $256,436.66. Following the sale, the chief financial officer now owns 177,449 shares of the company’s stock, valued at approximately $3,941,142.29. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 962,791 shares of company stock worth $16,930,725. Corporate insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Hims & Hers Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares during the last quarter. Forerunner Ventures Management LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter worth $86,836,000. Dimensional Fund Advisors LP boosted its holdings in shares of Hims & Hers Health by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after acquiring an additional 193,507 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Hims & Hers Health by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock worth $11,523,000 after purchasing an additional 22,009 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.